National Comprehensive Cancer Network

About NCCN

NCCN Guidelines® and NCCN Compendium® Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Kidney Cancer. These NCCN Guidelines® are currently available as Version 1.2015.

  • Predominant clear cell kidney cancer (KID-3)
    • First-line therapy
      • Axitinib was added to the list of options (category 2A).
    • Subsequent therapy
      • The use of pazopanib after tyrosine kinase therapy was changed from category 3 to category 2A.
      • The cytokine therapy, IL-2, was clarified as "High-dose IL-2 for selected patients" with a footnote defining selected cases, “Patients with excellent performance status and normal organ function.”

For the complete updated versions of the NCCN Guidelines, the NCCN Compendium®, and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit

To access the NCCN Biomarkers Compendium®, please visit

To view the NCCN Guidelines for Patients®, please visit

Free NCCN Guidelines apps iPhone, iPad, and Android devices are now available! Visit

 About NCCN Flash Updates™ 

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

Access information on permissions and licensing of NCCN Content  

© 2014 National Comprehensive Cancer Network. All Rights Reserved.